.2020 Sep 18;369(6510):eaas8995.

doi: 10.1126/science.aas8995.

HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation

Venkat Giri Magupalli^#^{1 2}, Roberto Negro^#^{1 2}, Yuzi Tian^#^{3 4}, Arthur V Hauenstein^#^{5 2}, Giuseppe Di Caprio^{2 6}, Wesley Skillern², Qiufang Deng^{3 4}, Pontus Orning^{7 8}, Hasan B Alam³, Zoltan Maliga⁹, Humayun Sharif^{5 2}, Jun Jacob Hu^{5 2}, Charles L Evavold¹⁰, Jonathan C Kagan¹⁰, Florian I Schmidt¹¹, Katherine A Fitzgerald^{7 8}, Tom Kirchhausen^{2 6}, Yongqing Li¹², Hao Wu^{1 2}

Affiliations

¹ Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. wu@crystal.harvard.edu venkat.magupalli@childrens.harvard.edu roberto.negro@childrens.harvard.edu yqli@med.umich.edu.
² Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
³ Department of Surgery, North Campus Research Complex, University of Michigan, Ann Arbor, MI 48109, USA.
⁴ Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁵ Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
⁶ Departments of Cell Biology and Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
⁷ Program in Innate Immunity, Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
⁸ Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
⁹ Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
¹⁰ Harvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA 02115, USA.
¹¹ Institute of Innate Immunity, Biomedical Center, University Hospitals, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
¹² Department of Surgery, North Campus Research Complex, University of Michigan, Ann Arbor, MI 48109, USA. wu@crystal.harvard.edu venkat.magupalli@childrens.harvard.edu roberto.negro@childrens.harvard.edu yqli@med.umich.edu.

^# Contributed equally.

PMID:32943500
PMCID: PMC7814939
DOI: 10.1126/science.aas8995

HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation

Venkat Giri Magupalli et al. Science.2020.

.2020 Sep 18;369(6510):eaas8995.

doi: 10.1126/science.aas8995.

Authors

Affiliations

¹ Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA. wu@crystal.harvard.edu venkat.magupalli@childrens.harvard.edu roberto.negro@childrens.harvard.edu yqli@med.umich.edu.
² Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA 02115, USA.
³ Department of Surgery, North Campus Research Complex, University of Michigan, Ann Arbor, MI 48109, USA.
⁴ Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁵ Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
⁶ Departments of Cell Biology and Pediatrics, Harvard Medical School, Boston, MA 02115, USA.
⁷ Program in Innate Immunity, Department of Medicine, Division of Infectious Diseases and Immunology, University of Massachusetts Medical School, Worcester, MA 01605, USA.
⁸ Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
⁹ Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
¹⁰ Harvard Medical School and Division of Gastroenterology, Boston Children's Hospital, Boston, MA 02115, USA.
¹¹ Institute of Innate Immunity, Biomedical Center, University Hospitals, University of Bonn, Venusberg-Campus 1, 53127 Bonn, Germany.
¹² Department of Surgery, North Campus Research Complex, University of Michigan, Ann Arbor, MI 48109, USA. wu@crystal.harvard.edu venkat.magupalli@childrens.harvard.edu roberto.negro@childrens.harvard.edu yqli@med.umich.edu.

^# Contributed equally.

PMID:32943500
PMCID: PMC7814939
DOI: 10.1126/science.aas8995

Abstract

Inflammasomes are supramolecular complexes that play key roles in immune surveillance. This is accomplished by the activation of inflammatory caspases, which leads to the proteolytic maturation of interleukin 1β (IL-1β) and pyroptosis. Here, we show that nucleotide-binding domain, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3)- and pyrin-mediated inflammasome assembly, caspase activation, and IL-1β conversion occur at the microtubule-organizing center (MTOC). Furthermore, the dynein adapter histone deacetylase 6 (HDAC6) is indispensable for the microtubule transport and assembly of these inflammasomes both in vitro and in mice. Because HDAC6 can transport ubiquitinated pathological aggregates to the MTOC for aggresome formation and autophagosomal degradation, its role in NLRP3 and pyrin inflammasome activation also provides an inherent mechanism for the down-regulation of these inflammasomes by autophagy. This work suggests an unexpected parallel between the formation of physiological and pathological aggregates.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

**Fig. 1.. NLRP3 and pyrin inflammasomes, but not the AIM2 inflammasome, co-localize with the MTOC.**
**(A)** The NLRP3, pyrin, and AIM2 inflammasome pathways triggered by nigericin or MSU, TcdB, and dsDNA, respectively. As shown below, NLRP3 and pyrin inflammasome puncta localize at the MTOC. Inflammasome activation culminates in pro-caspase-1 and pro-IL-1β processing. Upward arrows indicate processing sites.(B) Immunofluorescence images showing the co-localization of NLRP3 and ASC puncta with the centrosomal markers ninein and GTU in THP-1 cells. Blue represents nuclear staining by Hoechst 33342. (C) Line scan of intensity distribution profiles of puncta a, b, and c from (B).(D–E) Live-cell images of iBMDM-Casp-1 (D) and iBMDM-IL-1β (E) at 30 min (top panel) and 60 min (bottom panel) post-nigericin stimulation, showing co-localization of inflammasome puncta (depicted by mNeonGreen) with the MTOC (depicted by SiR-Tubulin staining that labels the microtubule network).(F) FRET analysis of caspase-1 cleavage and IL-1β processing at MTOC as a function of time for areas inside and outside the puncta in iBMDM-Casp-1 (left) and iBMDM-IL-1β (right) cells. FRET was calculated by dividing the FRET channel fluorescence intensity (donor excitation with acceptor emission) with mTurquoise2 channel fluorescence intensity (donor excitation with donor emission). Values are mean±SD for n=10–15 cells.(G–H) Recruitment of IL-1β to a region in proximity to the MTOC imaged using 3D lattice light-sheet microscopy (LLSM). iBMDM-IL-1β cells stained with SiR-Tubulin were exposed to nigericin for 12 min (G), and 23 min (H). (a–c) Representative images deconvolved using the Richardson–Lucy algorithm corresponding to a single optical plane section. The arrows highlight the MTOC and the nearby locations where IL-lβ was recruited. (d–f) Enlarged images of the regions indicated by the arrows.(I–J) Lack of co-localization of AIM2 inflammasome puncta with the MTOC in iBMDM-Casp-1 (I) and iBMDM-IL-1β (J) cells activated by dsDNA for 6 hours.(K–L) Co-localization of pyrin inflammasome puncta with the MTOC in iBMDM-Casp-1 (K) and iBMDM-IL-1β (L) cells activated by TcdB toxin for 1 hour. Images are representative of three or more independent experiments and arrowheads indicate puncta or MTOC (B, D–E, G–L). Scale bars: 10 μm (B, D–E), 5 μm (Ga–c, Ha–c, I–L), and 1 μm (Gd–f, Hd–f).

**Fig. 2.. Microtubule retrograde transport is required for the activation of NLRP3 and pyrin inflammasomes, but not the AIM2 inflammasome.**
**(A–C)** NLRP3 inflammasome activation under various inhibition conditions analyzed by caspase-1 processing (p20) (A), quantification of propidium iodide (PI) permeability by flow cytometry (B), and secreted IL-1β quantified by ELISA (C). Colchicine and nocodazole: microtubule polymerization inhibitors; Ciliobrevin A: dynein ATPase inhibitor; Rocilinostat, tubacin and tubastatin A: HDAC6 inhibitors.(D) Caspase-1 processing (p20) upon NLRP3 inflammasome activation with pre-treatment of increasing concentrations of tubacin (left to right: 5 μM, 10 μM, 20 μM and 40 μM) or the NLRP3 inhibitor MCC950 (left to right: 0.1 μM, 0.5 μM, 1 μM, 10 μM and 20 μM). Anti-acetylated α-tubulin and anti-β-actin immunoblots are shown for tubulin acetylation and as the loading control, respectively.(E–G) Pyrin inflammasome activation under various pharmacological conditions analyzed by caspase-1 processing (p20) (E), PI permeability (F), and secreted IL-1β (G).(H–J) AIM2 inflammasome activation under various pharmacological conditions analyzed by caspase-1 processing (p20) (H), PI permeability (I) and secreted IL-1β (J). Data are presented as the mean±SD for 3–4 wells from three or more independent experiments.

**Fig. 3.. HDAC6 is required for NLRP3 inflammasome activation.**
**(A)** Immunoblotting shows the absence of HDAC6 protein in CRISPR/Cas9Hdac6^−/− iBMDMs as compared to WT iBMDMs. Loading control was provided by the anti-β-actin antibody. The loss of HDAC6 leads to an increase in acetylated α-tubulin depicted using anti-acetylated α-tubulin antibody.(B–D) Compromised NLRP3 inflammasome activation inHdac6^−/− iBMDMs challenged with nigericin, shown for caspase-1 processing (B), PI permeability (C), and secreted IL-1β (D). Data are presented as the mean±SD for triplicate wells from three or more independent experiments (C, D).(E) Domain architecture of human HDAC6 with important mutations (DA, Ub1 and Ub2) labeled. DA: H216A/H611A on catalytic residues, deacetylase mutant; Ub1: mutations H1160A/H1164A on zinc-coordinating residues; Ub2: mutation W1182A on the surface that binds ubiquitin.(F) Rescue of nigericin-mediated caspase-1 processing inHdac6^−/− iBMDMs by reconstituting with WT human HDAC6.(G) Analysis of nigericin-mediated caspase-1 processing inHdac6^−/− iBMDMs reconstituted with WT HDAC6, and the DA, Ub1 and Ub2 mutants.(H) Sensitivity to rocilinostat inHdac6^−/− iBMDMs reconstituted with WT HDAC6, but not the DA mutant, as depicted by inhibition of p20 processing.(I) Rescue of nigericin-induced punctum formation inHdac6^−/− iBMDM-Casp-1 cells transfected with WT HDAC6-mRuby3. Arrowheads indicate puncta. Cells containing puncta had HDAC6 expression (a and b), whereas cells that do not contain puncta did not have HDAC6 expression (c and d). (J) Rescue of nigericin-induced punctum formation inHdac6^−/− iBMDM-Casp-1 cells stably reconstituted with WT and DA mutant of HDAC6-mRuby3, but not with Ub1 and Ub2 mutants of HDAC6-mRuby3. Arrowheads indicate puncta. HDAC6 WT reconstituted cells failed to form puncta upon pretreatment by rocilinostat.(K–L) Inflammasome puncta formation and its link to autophagy analyzed by immunofluorescence of ASC and the autophagy marker LC3b before (K) and after (L) NLRP3 inflammasome stimulation. Arrowheads indicate puncta. Images are representative of three or more independent experiments. Scale bars: 10 μm.

**Fig. 4.. HDAC6 is required for pyrin inflammasome activation, but not AIM2 inflammasome activation.**
**(A–D)** Requirement of HDAC6 and its ubiquitin binding ability in TcdB-induced pyrin inflammasome activation, shown by caspase-1 processing (p20) (A), PI permeability (B), IL-1b secretion (C), and punctum formation (D). DA: H216A/H611A on catalytic residues, deacetylase mutant; Ub1: mutations H1160A/H1164A on zinc-coordinating residues; Ub2: mutation W1182A on the surface that binds ubiquitin.(E–H) Lack of HDAC6-dependence in dsDNA-induced AIM2 inflammasome activation, shown by caspase-1 processing (p20) (E), PI permeability (F), IL-1b secretion (G), and punctum formation (H). Arrowheads indicate puncta or MTOC. Data are presented as the mean±SD for triplicate wells from three or more independent experiments (B, C, F, G). Images are representative from three or more independent experiments (D, H). Scale bars: 5 μm.

**Fig. 5.. HDAC6 deficiency does not affect non-canonical and NLRC4 inflammasome activation inNlrp3^−/− background.**
**(A–B)** Non-canonical inflammasome activated by intracellular delivery of LPS (electroporation) quantified by PI permeability (A) and FAM-FLICA™ substrate cleavage by active caspase-11 (B).(C–D) NLRC4 inflammasome activation triggered by active FlaTox (inactive FlaTox served as a control) analyzed for caspase-1 processing (p20) (C), and PI permeability (D). Data are presented as the mean±SD for triplicate wells from three or more independent experiments.(E) Immunofluorescence analysis of NLRC4 punctum formation inNlrp3^−/− (top) andNlrp3^−/−*Hdac6*^−/− (bottom) iBMDMs upon treatment with FlaTox. Blue represents nuclear staining by Hoechst 33342. The NLRC4 inflammasome punctum represented by ASC staining is distinctly apart from the centrosomal marker ninein. Arrowheads depict puncta or MTOC. Images are representative of three or more independent experiments. Scale bars: 5 μm. (F) Summary of location of punctum formation and HDAC6-dependence in the different inflammasomes.

**Fig. 6.. HDAC6 mediates microtubule transport of trans-Golgi network (TGN)-localized NLRP3.**
**(A–C)** Immunofluorescence analysis of TGN38 and NLRP3 inAsc^−/− iBMDMs (A), WT iBMDMs (B) andHdac6^−/− iBMDMs (C). (D) Immunofluorescence analysis of NEK7 and NLRP3 distribution inHdac6^−/− iBMDMs. Images are representative of three or more independent experiments containing ~100 cells. Arrowheads depict puncta. Scale bars: 10 μm.

**Fig. 7.. HDAC6 is required for NLRP3 inflammasome activation in mice.**
**(A–F)** A mouse model of lethal LPS-induced endotoxemia. (A) Experimental layout with indicated timing and dose.(B–D) Effects of tubastatin A (HDAC6 inhibitor) (B),*Hdac6*^−/− (C), or MCC950 (NLRP3 inhibitor) (D) on IL-1β secretion. Values are mean±SD (n=3–5/group).(E) Effects of tubastatin A on acute lung injury (ALI). Representative histopathological images from harvested lung tissues are shown. Scale bar: 50 μm. (F) Quantified lung injury depicted by defined clinical parameters in ALI score. ALI scores are mean±SD (n=3–4/group).(G–K) A mouse model of MSU-induced peritonitis.(G) Experimental layout with indicted timing and dose.(H–I) Effects ofHdac6^−/− orHdac6^−/− + MCC950 on peritoneal IL-1β production (H) and neutrophil recruitment (I) upon MSU challenge. Values are mean±SD (n=6–7/group).(J–K) Effects of MCC950 on peritoneal IL-1β production (J) and neutrophil recruitment (K) upon MSU challenge. Values are mean±SD (n=5–8/group). For (B–D, F, H–K), one-way analysis of variance (ANOVA) followed by Bonferroni’s multiple comparison test was performed for data analysis as used previously (64, 65). *:P≤0.05, **:P≤0.01, ***:P≤0.001 and ****:P≤0.0001.

See this image and copyright information in PMC

Cited by

Structural and functional modelling of SARS-CoV-2 entry in animal models.
Brooke GN, Prischi F.Brooke GN, et al.Sci Rep. 2020 Sep 28;10(1):15917. doi: 10.1038/s41598-020-72528-z.Sci Rep. 2020.PMID:32985513Free PMC article.
Mushroom Natural Products in Neurodegenerative Disease Drug Discovery.
Abitbol A, Mallard B, Tiralongo E, Tiralongo J.Abitbol A, et al.Cells. 2022 Dec 6;11(23):3938. doi: 10.3390/cells11233938.Cells. 2022.PMID:36497196Free PMC article.Review.
Organellar homeostasis and innate immune sensing.
Harapas CR, Idiiatullina E, Al-Azab M, Hrovat-Schaale K, Reygaerts T, Steiner A, Laohamonthonkul P, Davidson S, Yu CH, Booty L, Masters SL.Harapas CR, et al.Nat Rev Immunol. 2022 Sep;22(9):535-549. doi: 10.1038/s41577-022-00682-8. Epub 2022 Feb 23.Nat Rev Immunol. 2022.PMID:35197578Review.
Myddosome clustering in IL-1 receptor signaling regulates the formation of an NF-kB activating signalosome.
Cao F, Deliz-Aguirre R, Gerpott FH, Ziska E, Taylor MJ.Cao F, et al.EMBO Rep. 2023 Oct 9;24(10):e57233. doi: 10.15252/embr.202357233. Epub 2023 Aug 21.EMBO Rep. 2023.PMID:37602973Free PMC article.
NLRP3 is essential for neutrophil polarization and chemotaxis in response to leukotriene B4 gradient.
Van Bruggen S, Jarrot PA, Thomas E, Sheehy CE, Silva CMS, Hsu AY, Cunin P, Nigrovic PA, Gomes ER, Luo HR, Waterman CM, Wagner DD.Van Bruggen S, et al.Proc Natl Acad Sci U S A. 2023 Aug 29;120(35):e2303814120. doi: 10.1073/pnas.2303814120. Epub 2023 Aug 21.Proc Natl Acad Sci U S A. 2023.PMID:37603754Free PMC article.

See all "Cited by" articles

References

1. Broz P, Dixit VM, Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol 16, 407–420 (2016). - PubMed
1. Rathinam VA, Vanaja SK, Fitzgerald KA, Regulation of inflammasome signaling. Nat Immunol 13, 333–332 (2012). - PMC - PubMed
1. Lamkanfi M, Dixit VM, Mechanisms and functions of inflammasomes. Cell 157, 1013–1022 (2014). - PubMed
1. Strowig T, Henao-Mejia J, Elinav E, Flavell R, Inflammasomes in health and disease. Nature 481, 278–286 (2012). - PubMed
1. Back M, Hansson GK, Anti-inflammatory therapies for atherosclerosis. Nature reviews. Cardiology 12, 199–211 (2015). - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Related information

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
Molecular Biology Databases
- Mouse Genome Informatics (MGI)
Research Materials
- Addgene Non-profit plasmid repository

Movatterモバイル変換

Account

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Full text links

Actions

Share

HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation

Affiliations

HDAC6 mediates an aggresome-like mechanism for NLRP3 and pyrin inflammasome activation

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources

Molecular Biology Databases

Research Materials